IDEAYA Biosciences, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
IDEAYA Biosciences, Inc. (IDYA) reported Adjustments to Additional Paid in Capital, Warrant Issued of $141.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-04
- IDEAYA Biosciences, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-06-30 was $141.00M.
- IDEAYA Biosciences, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- IDEAYA Biosciences, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-09-30 was $9.40M.
- IDEAYA Biosciences, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-12-31 was $7.05M.
- IDEAYA Biosciences, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $9.40M, a 77.72% decline from fiscal 2023.
- IDEAYA Biosciences, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2023 was $42.18M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2026-06-30 | $141.00M 10-Q · filed 2026-08-04 | $141.00M 10-Q · filed 2026-08-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $9.40M derived: sum of 2 quarters · filed 2026-02-17 | $9.40M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $9.40M 10-Q · filed 2025-11-04 | $9.40M 10-Q · filed 2025-11-04 | ||
| 2023-12-31 | $7.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $7.05M derived: sum of 2 quarters · filed 2026-02-17 | $42.18M derived: sum of 3 quarters · filed 2026-02-17 | $42.18M 10-K · filed 2026-02-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $35.13M derived: sum of 2 quarters · filed 2024-11-04 | $35.13M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $35.13M 10-Q · filed 2024-08-06 | $35.13M 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |